top of page
Search by
Poster Number
1, 2, 3, 4,
5, 6, 7, 8,
9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Click on the Poster to View the Poster Page
All Posters
POSTER 25
Treatment-Free Disease Control After Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Tina Bhutani,...
POSTER 26
Combined Skin Clearance and Quality of Life Response in Patients With Moderate-to-Severe Atopic Dermatitis With and Without Prior...
POSTER 27
Impact of Baseline Disease Severity on the Long-Term Efficacy and Safety of Abrocitinib Treatment in Adolescent Patients With...
POSTER 28
Effect of Abrocitinib and Dupilumab on the Incidence of Conjunctivitis in Patients With Atopic Dermatitis: An Analysis of Abrocitinib...
POSTER 29
Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab Thomas Bieber, Eric L. Simpson,...
POSTER 30
Dupilumab Safety and Efficacy Up To 3 Years in Children Aged 6 Months to 11 Years with Atopic Dermatitis Amy S. Paller, Eric L. Simpson,...
POSTER 31
Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dose Regimens Eric...
POSTER 32
Sustained Disease Control Among Adults with Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the...
POSTER 33
Dupilumab Treatment Reduces Medium- and High-Potency Topical Corticosteroid Usage in Pediatric Patients Aged 6 Months to 5 Years With...
POSTER 34
Dupilumab Reduces Severity and Lesion Extent in Children <12 Years with Moderate-to-Severe AD: 4-Year Results from the PEDISTAD Registry...
POSTER 35
Dupilumab Efficacy in Pooled LIBERTY-CSU CUPID Study A and Study C Regardless of Baseline Total Serum IgE Levels Sarbjit S. Saini, MD,...
POSTER 36
Kyrle's Disease: Dermatologic Manifestations of Systemic Disease Jung Sung, MS, PA; Curt Samlaska, MD < Previous Poster | Next Poster >...
POSTER 37
“Super-Response” Following Treatment with Delgocitinib Cream 20 mg/g in a Subgroup of Patients with Moderate to Severe Chronic Hand...
POSTER 38
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib and Dupilumab in the Treatment of Moderate to Severe Atopic Hand...
POSTER 39
Delgocitinib Cream 20 mg/g in Chronic Hand Eczema Patients with Skin Fissures: Efficacy, Safety, and Pharmacokinetics Lawrence F...
POSTER 40
Delgocitinib Cream Has Negligible Systemic Exposure in Patients with Maximal Use of Delgocitinib Cream for the Treatment of Chronic Hand...
POSTER 41
Delgocitinib Cream Provides Early and Meaningful Responses in Adults with Moderate to Severe Chronic Hand Eczema: A Pooled Analysis of...
POSTER 42
Dupilumab Provides Early and Sustained Improvement in Itch in Patients With Chronic Spontaneous Urticaria: Pooled Results From...
POSTER 43
Efficacy and Safety of Deucravacitinib in Patients With Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus...
POSTER 44
Daily Use of a Novel Cream Improves Thinning, Pre-Dermatoporosis Skin Alan Widgerow, MBBCh, MMed, FCS, FACS; Sarah Anjuwon, Mathieu...
POSTER 45
Bimekizumab Impact on Flare in Hidradenitis Suppurativa Over 2 Years: Data from BE HEARD EXT Haley B. Naik, Steven Daveluy, Errol Prens,...
POSTER 46
Use of Non-Prescription Topical Nitric Oxide Releasing Preparations for Dermatological Infections Gilly Regev, PhD; Chris Miller, PhD <...
POSTER 47
A Non-Prescription Nitric Oxide Releasing Gel Demonstrates In Vitro Anti-Fungal Activity and Supports Nail Clearance in Patients with...
POSTER 48
Avapritinib Durably Improves Cutaneous Involvement of Indolent Systemic Mastocytosis in Patients Treated in the PIONEER Study Frank...
bottom of page